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1. Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortalities in the Western
world, with over 1.2 million new cases and over 0.6 million deaths being recorded in 2008 [1].
Major risk factors of CRC are personal history of precursor lesion, inflammatory bowel disease,
age (about 90% of cases occur after age 50) and family history of CRC or a genetic susceptibility
to the development of CRC resulting from DNA mutations. It is estimated that approximately
15% of CRC cases develop as a result of inherited factors and 5-10% of them result from known
genetic syndroms, e.g., familial adenomatous polyposis (FAP) and hereditary non-polyposis
colorectal carcinoma (HNPCC), while most cases of CRC occurs sporadically (70-80%) [2]. In
patiens with inherited genetic factors CRC occurs early in life, usualy before 40 years of their
age, while in sporadic cases cancer develops after 40 years of age with the highest incidence
between 60 and 70 years of age. CRC remains asymptomatic for years. Symptoms develop
insidiously and are frequently present for months, sometimes years, before being diagnosed.
If colon tumors are not identified and removed at the precancerous or adenoma stage, the
disease gradually progresses into carcinoma stage where cancer cells invade the wall of the
intestine and distant organs [1].
There are different approaches and strategies concerning how to reduce the mortality due to
CRC. The surgical and chemotherapeutic treatment of CRC is usually costly, painful and the
prognosis is not promisig. Therefore, in clinical practice efforts have been directed toward
identification and removal of precancerous lesions. Screening programs, which are based upon
detection and removal of visible polypoid adenomas, have been implemented in a number of
countries on nationwide scale.
Global cancer statistics shows that CRC-related mortality has been decreasing in Western
countries due to improved treatment and early detection, which indicates that screening
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program is one of the important steps in reducing the mortality due to CRC [1]. However,
although screening programs are promising and represent one of the important steps in
reducing the mortality due to CRC, reports demonstrate that there is still 25% of false-negative
results due to flat or depressed precancerous lesions, which are commonly missed during
conventional colonoscopy [3].
Recently, another promising approach has been demonstrated. It is directed toward identifi‐
cation of aberrant crypt foci (ACF), intermediate biomarkers predictive for CRC. The associa‐
tion of ACF with CRC is supported by shared histological and molecular features of ACF with
colonic polyps and adenomas [4-7].
The aim of the present chapter is to summarize experimental and clinical results regarding
morphological, histological and molecular characteristics of ACF with emphasis on current
progress in the knowledge of CRC development. The role, significance and applicability of
ACF in clinical practice is also presented and discussed.
2. Aberrant crypt foci (ACF)
ACF are the first lesions in multistep development of CRC, which can be seen on the colon
surface with aid of magnification and/or dye.
ACF were first identified in 1987 by Bird on whole unembedded colon of carcinogen treated
mouse [8]. Colon was fixed, stained with methylene blue and observed under low-magnifi‐
cation (10-40x M) stereomicroscope [9; 10]. This simple and rapid methodological approach
enabled visualization of all crypts on the surface of the colon mucosa. Since their first identi‐
fication numerous studies investigating morphology, distribution, histology and molecular
characteristics of ACF have been performed. In 1991 reports on identification of ACF in the
human colon were published. ACF were identified under a dissecting microscope after
methylene blue staining on the mucosal surface of both formalin-fixed human colon resections
and fresh (unfixed) colon resections [11-13].
Based on morphological appearance of crypts on the colon surface crypts can be regarded as
normal or aberrant. Aberrant crypts can be observed as single altered crypt or as a cluster of
altered crypts that form a focus termed ACF [8; 14; 15].
It is important to keep in mind that ACF is a term that denotes topographic or endoscopic
observation. ACF can be identified as clusters of altered crypts in unembedded colon mucosa
(fixed or fresh) under magnification after visualization by different dyes. In studies using
animal models ACF are usually observed under stereomicroscope on whole colon mucosa that
is fixed flat (to prevent excessive unevenness while viewing) and stained with methylene blue
[9; 10]. In clinical practice ACF can be observed in vivo endoscopically with aid of dye spray
(methylene blue or indigo carmine) using high magnification colonoscopy [6; 7; 16].
ACF is not a histological diagnosis. Structural and cytological features of ACF can be recog‐
nized or confirmed only after histological examination. However, at the same time it is
noteworthy to mention that lesions seen in histologic sections of colon without prior topo‐
graphic identification on colon surface can not be termed ACF.
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To better understand the histological background of ACF as well as molecular alterations
recognized and described at this stage of colon carcinogenesis, the next section is brief
overview of histological criteria and classification of ACF, histologically denoted as colorectal
intraepithelial lesions [17; 18].
3. Histological characteristics of ACF
Histologically, ACF are heterogeneous group of intraepithelial lesions that exhibit variable
features, ranging from almost normal or mild atypia to severe dysplasia. Based on their
histological characteristics they can be divided into three main categories [7; 14]:
1. ACF that are almost histologically normal,
2. ACF with hyperplastic crypts and
3. ACF with dysplastic crypts.
According to World Health Organization ACF are histologically classified into two groups,
i.e. ACF with hyperplastic crypts and ACF with dysplastic crypts [19].
It has been demonstrated that the majority of observed ACF, including ACF identified in
patients with sporadic CRC, are classified as almost histologically normal (Figure 1). These
ACF are composed of crypts with almost normal histological appearance. The major histologic
difference that distinguishes this type of ACF from normal crypts is slightly enlarged crypt
diameter. The crypt diameter in this type of ACF measures up to 1.5 times the diameter of a
normal crypt. They show no other histological or molecular alterations and they even spon‐
taneously regress. Accordingly, it was found that this type of ACF has no clinical diagnostic
value [7; 14].
Figure 1. A normal human (left) and rat (right) colorectal mucosa. Crypts are parallel. The mucin is stained blue (Krey‐
berg trichrom stain).
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On the other hand, other two groups of ACF have been found to have potential clinical value
as biomarker predictive for CRC risk [7; 14].
4. ACF with hyperplastic crypts (hyperplastic intraepithelial lesions)
Hyperplastic epithelial lesions are composed of mixture of goblet and absorptive cells with
enlarged or sometimes crowded nuclei without stratification (Figure 2).
Figure 2. Hyperplastic aberrant crypts of human (left) colorectal mucosa accompanying resected sporadic colorectal
adenoma. The focus is composed of 3 hyperplastic crypts that are much wider then surrounding normal crypts. The
epithelial cells of the hyperplastic crypts are higher and composed of one layer. On the right there are hyperplastic
aberrant crypts of rat colorectal mucosa, induced by carcinogen. The focus is composed of 3 crypts with slight mucin
depletion. The level of focus is higher then of the surrounding mucosa. The epithelial cells of the hyperplastic crypts
are higher and composed of one layer (Kreyberg trichrom stain).
Mitotic figures are limited to the lower two-thirds of the crypts and are never observed on the
surface of crypts. Nuclei are basally located, ovoid or round, with occasional visible nucleoli
and usually uniformly dark. The luminal opening of crypts is slightly elevated from the
surrounding normal mucosa and the crypts are elongated and occasionally branching with
partial mucin depletion [17]. The role of hyperplastic aberrant crypts in the process of colon
carcinogenesis is not clear and is a matter of debate and further investigations [15].
5. ACF with dysplastic crypts (intraepithelial neoplasia/dysplasia)
Presence of dysplasia is regarded as early histopathological changes in the precursor lesions
of colon cancer. The word dysplasia is histological term that describes structural and cytolog‐
ical alterations in the epithelium that predispose an organ to cancer development. Inraepithe‐
lial neoplasia (IEN) is a histological term for dysplastic lesions in the epithelial layer of colon
mucosa that can be identified only after careful histological examination (Figure 3). IEN is
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synonymous with terms atypical hyperplasia, microadenoma, carcinoma in situ and dysplasia.
Depending on cytological and architectural features IEN is classified as low-grade or high
grade. The differential histological criteria involve hypercellularity with enlarged, hyperchro‐
matic nuclei, varying degrees of nuclear stratification, loss of polarity, high nuclear/cytoplas‐
mic ratio, nuclear crowding, increased mitotic index and decreased mucin excretion [17; 20].
Figure 3. Dysplastic aberrant crypts of human colorectal mucosa accompanying FAP (left). The focus is composed of 4
crypts. The level of focus is higher then that of the surrounding mucosa. The epithelial cells covering the aberrant
crypts are classified as mild dysplasia. On the right there are dysplastic aberrant crypts of rat colorectal mucosa in‐
duced by carcinogen. The focus is composed of 3 crypts that show severe mucin depletion. Numerous mitoses, stratifi‐
cation of nuclei, atypical epithelial cells, and architectural atypia are the components of dysplasia (Kreyberg trichrom
stain).
6. Molecular characteristics of ACF
Evidence from experimental and clinical studies demonstrates that ACF share similar histo‐
logical and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas) [15; 21;
22]. Today, high-magnification chromoscopic colonoscopy allows detection and biopsy of ACF
in vivo in man. It also provides opportunity to investigate and characterize the earliest genetic
and molecular alterations in CRC development in man. ACF exhibit many of the molecular
and genetic abnormalities that form the basis for the adenoma-carcinoma sequence in CRC.
It has been found that ACF exhibit many of the molecular and genetic abnormalities that form
the basis for the adenoma-carcinoma sequence in CRC. Genetic alterations found in human
ACF include mutations in tumor suppressor genes, microsatellite instability, aberrant meth‐
ylation as well as aberrant expression of proteins (summarized in Figure 4). Up to date, three
molecular pathways of CRC development have been identified and described, i.e. chromoso‐
mal instability, microsatellite instability and CpG island methylator phenotype. All three types
of molecular alterations have also been found in ACF [22; 23].
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Figure 4. Phenotypic, genetic and epigenetic alteration involved in multistep development of colon carcinogenesis.
7. The chromosomal instability (CIN)
CIN is the most common in sporadic CRC and shows chromosomal abnormalities such as
chromosome breaks, duplication, rearrangements, loss of heterozygosity (LOH) and sequen‐
tial inactivation of tumor suppressor genes such as APC (5q), P53 (17p) and SMAD4 (18q),
which are frequently found in sporadic carcinomas. It is known that germ line mutations in
APC lead to the hereditary syndrome of FAP [22; 23].
Loss of heterozygosity (LOH) was observed in ACF at 18q (locus that maps close to the DCC
and DPC4 genes) [24], in 67% LOH was found at locus 11p11, the location of the gene for protein
tyrosine phosphatase receptor type J (PTPRJ; tumor suppressor gene), at locus 5q21 and 18q21
[25]. LOH was identified near the APC tumor suppressor gene (at the D5S346 marker) [26].
APC mutation was found in ACF with dysplastic crypts but not in ACF with hyperplastic
crypts. This was frequently observed in ACF obtained from patients with FAP, while in ACF
obtained from patients with sporadic CRC APC mutation was rarely observed [7; 27; 28].
β-catenin mutation, which is found in 12% of adenomas and 16% of carcinomas, was not found
in ACF, regardless of the histologic type of ACF [5; 29]. Only increased expression of β-catenin
was found in the cytosol of ACF with dysplastic crypts (54%) [30; 31].
K-RAS mutation was found in 13%-95% of ACF and was much more frequent in ACF with
hyperplastic crypts (80%-100%) that in ACF with dysplastic crypts (0%-57%) [7; 27; 28; 32-35].
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8. The microsatellite instability (MSI)
MSI is a hallmark of defective DNA mismatch repair (MMR) genes such as hMLH1 or hMSH2
and leads to the accumulation of a high frequency of somatic mutations [24]. It is frequent in
patients with HNPCC (90%) but also found in sporadic CRC (15%).
MSI was identified in 30% ACF from patients of elevated risk (family or personal history) and
13% lesions from average risk patients (subjects without family or personal history) [24-26].
9. The CpG island methylator phenotype (CIMP)
CIMP is epigenetic mechanism characterized by hypermethylation of cytosine residue within
CpG islands in the promoter regions of certain genes (which are particularly rich in CpG
nucleotides such as tumor suppressor and MMR genes) and results in their inactivation (loss
of gene expression). Genes that have been shown to be silenced by promoter hypermethylation
in human CRC are p16, hMLH1, MGMT, MINT1,2,12, and 31 [22; 23].
Methylation of CpG islands was found in 34% ACF obtained from patients with both FAP and
sporadic CRC, but was more frequent in sporadic ACF (53%), especially dysplastic ACF (75%)
and less hyperplastic ACF (7%) [32].
In ACF hypermethylation of the MMR genes such as hHLM1 and MGMT (in hyperplastic ACF)
[26] and tumor suppressor genes such as p16, MINT31 [32], RASSF1A were found [26].
10. ACF revealing new insight into CRC development
As high-magnification chromoscopic colonoscopy now allow detection and biopsy of ACF in
the mucosa of large bowel, ACF might serve as a research tool for revealing new insights and
knowledge into first alterations and risk factors in CRC development.
Evidence shows that ACF in FAP patients differ from ACF in subjects with sporadic CRC.
Differences can be observed regarding endoscopic, histological and molecular characteristics.
Patients with FAP have significantly increased number of ACF than patients with sporadic
CRC. Most of the ACF in FAP patients is histologically diagnosed as dysplastic (89%), while
patients with sporadic CRC have mostly ACF with hyperplastic crypts (82%). K-RAS mutation
was found very rarely in dysplastic ACF of FAP patients, but frequently in ACF obtained from
patients with sporadic CRC (82%) [7].
Conversely, APC mutations were very rarely found in dysplastic ACF from patients with
sporadic CRC, while in ACF from FAP patients were almost always present. Methylation of
CpG islands was found in sporadic ACF but not in ACF from FAP patients [32].
Differences in the endoscopic appearance and genetic features were observed also in ACF
obtained from patients with ulcerative colitis (UC). In ACF from patients with UC K-RAS
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mutation was rarely observed and APC mutation was not found. However, in dysplastic ACF
frequent methylation of promoter region of p16 (73%) and P53 mutation (60%) was found [36].
All these data show that ACF provide opportunity to get closer insight into first molecular
events that are responsible for initiation and formation of CRC.
11. Endoscopic characteristics of ACF
As already mentioned ACF are the first lesions that can be found on the surface of the fixed or
fresh colorectal mucosa. ACF are invisible to standard endoscopic instruments but can now
be visualized in vivo endoscopically by using specialized magnifying colonoscopes in con‐
junction with dye sprays (methylene blue, indigo carmine), the technique termed high-
magnification chromoscopic colonoscopy [6].
Staining of the colonic mucosa at colonoscopy improves the visibility of the morphological
characteristics of the crypts in the mucosa, such as shape, size or luminal openings of the crypts.
Most prominent feature of aberrant crypts is that they stain more darkly than do normal
surrounding crypts. However, there are also other morphological features important for
identification of ACF. By definition, ACF are colon crypts that are larger than normal sur‐
rounding crypts, have increased pericryptal space that separates them from the normal crypts,
they have a thicker layer of epithelial cells that often stains darker, their luminal openings are
not circular but rather oval or even compressed. They are usually not in the same level as the
surrounding normal crypts but they are either slightly elevated above the mucosa or may be
even depressed. ACF may be composed of one to few hundreds of aberrant crypts per focus
(1 to 412) [10; 14; 15].
As explained, ACF are heterogeneous group of lesions that exhibit variability in histological
and molecular characteristics as well as variability in morphological characteristics.
Based on the surface morphologic features of ACF, researchers are able to distinguish three
types of ACF and predict histologic characteristics of ACF [6].
Aberrant crypts that stain more darkly and are larger, have a thicker epithelial lining and a
larger pericryptal zone than normal crypts and exhibit large oval (smooth, dilated) lumens
have been histologically diagnosed as almost normal. Such ACF have slight enlargement,
irregularity, and elongation of the ducts but show no signs of hyperplasia or dysplasia [6].
Aberrant crypts that have all above-mentioned characteristics and exhibit asteroid or slit shape
of lumens have been histologically diagnosed as hyperplastic with serrated luminal pattern.
Aberrant crypts that have ticker epithelial lining than both above mentioned types and exhibit
compressed or undistinguishable lumen are classified in the third group of ACF, histologically
diagnosed as dysplastic. Such ACF show loss of polarity, hyperchromatism and stratification
of the nuclei in the crypt epithelium [6; 12; 14].
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12. Prevalence and density of ACF
First data about density (average number of ACF per cm2 of mucosa) and anatomical location
of ACF in colonic mucosa are based on investigations of colorectal resections. Results have
shown that patients with increased risk (personal or family history) have higher average
number of ACF per cm2 than persons with average risk (subjects without personal or family
history). It was found that FAP patients have significantly higher density of ACF in colon
mucosa than patients with sporadic CRC or benign bowel disease. Higher frequencies of ACF
were observed in left than in right colon. Results have shown that density of ACF increases
from proximal to distal part of the colon, being the highest in the rectosigmoidal region, which
corresponds to anatomical location of CRC development [11-14; 34].
13. Endoscopic detection of ACF
Similar findings regarding prevalence and distribution of ACF in colorectal mucosa have been
observed in humans in vivo by using magnifying (40x) endoscopy after endoscopic staining of
colon mucosa (methylene blue). Takayama et al. [6] examined 370 subjects (147 normal
subjects, 130 patients with adenoma, and 48 patients with carcinoma) and found that ACF were
present in almost all patients with adenoma or carcinoma. ACF were most frequently observed
in the left colon, where polyps are often found. Additionally, it was found that patients with
adenoma or carcinoma had significantly higher estimated relative risks for ACF with dys‐
plastic crypts than normal subjects [6].
In normal subjects, both the prevalence and the number of ACF in subjects under 40 years of
age were very low (10%) but increased with age, particularly after the age of 40 (54% - 66%).
Conversely, patients with cancer had a consistently high prevalence (100%) and large number
of ACF regardless of age. In patients with adenoma, the age-associated increment in the
prevalence and number of ACF was intermediate [6].
Takayama et al. [6] investigated number, density, and dysplastic features of distal colorectal
ACF in patients with exophytic adenomas and carcinomas, while Hurlstone et al. [16] assessed
the prevalence and features of ACF in patients with flat and depressed colorectal neoplastic
lesions, which account for around one third of all colorectal lesions. High magnification
chromoscopic colonoscopy was performed on 574 healthy subjects, 281 patients with flat
adenomas and 14 patients with flat carcinomas in which 602 (3% of them dysplastic), 2796 (18%
dysplastic) and 594 (61 % dysplastic) ACF were identified, respectively. Similarly as in patients
with exophytic colorectal lesions, the number of ACF increased in a stepwise fashion from
normal subjects to patients with flat or depressed adenoma and then to patients with flat or
depressed carcinoma [16].
In another study 103 patients with average age of 61 (range of 28-87) were examined by using
magnification (60x) chromoscopic colonoscopy. 788 ACF were found in the distal 20 cm of
colon/rectum. Patients with a family history of CRC had a significantly higher mean number
of ACF than the average risk subjects (7.6% dysplastic and 46% hyperplastic) [5].
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Rudolph et al. [37] have demonstrated that the number of ACF is significantly increased in
patients with personal history of adenoma in comparison to subjects without personal or
family history. They also observed that number of ACF is higher in older persons than in
younger subjects [37].
14. Clinical application
Clinical application of ACF as an intermediate biomarker for CRC in humans is under
development and is thus less conclusive [4; 38].
Recently, few studies investigated relationship of human colorectal ACF and formation of
colorectal polyps on repeat colonoscopy. It was found that the number of ACF in the colorec‐
tum was associated with substantial risk for future advanced neoplasia [39-42].
Ohkubo et al. [39] investigated natural history of human ACF and correlation with risk factors
for CRC. They examined 82 subjects who underwent total colonoscopy and whose ACF
number was examined at least 2 times. They retrospectively evaluated the changes in the ACF
number at four different surveillance periods (6 months, 1 year, 2 years, 3 years) and in groups
with and without colorectal neoplasms. The subjects were classified into an increased ACF
group and a no change/decreased ACF group, and investigated the relationship between the
changes in the ACF number and known risk factors for CRC. No significant differences were
observed in the ACF number between the first and second observations in any surveillance
period groups, and in the groups classified according to the presence or absence of colorectal
neoplasms. There were no significant differences between the increased and no change/
decreased ACF groups in terms of gender, smoking habit, current alcohol consumption, age,
BMI, HbA1c or serum triglyceride level, whereas a significant difference between the groups
was observed in the serum total cholesterol level [39].
All these data strongly implicate that detection and quantification of ACF in the distal colon
may be useful in predicting CRC risk and may be considered as a useful marker in chemo‐
preventive trials. Furthermore, it is expected that one of the most important clinical applica‐
tions of ACF observation with magnifying endoscopy will be its use as a target lesion for
chemoprevention. Because ACF are small lesions, they are suggested to be eradicated during
a short time by administration of chemopreventive agents [43]. Takayama et al. [43] performed
an open chemopreventive trial of sulindac and found that the number of ACF was reduced
markedly in 2 months. Patients receiving sulindac for more than one year had no ACF in colon
mucosa. After 8 to 12 months of follow-up, the number of ACF in colorectal mucosa signifi‐
cantly decreased or even completely disappeared. In the untreated control subjects the number
of ACF was either unchanged or slightly increased [6]. Another short-term chemoprevention
trial of metformin for colorectal ACF showed suppressive effect of the drug on the formation
of ACF [44]. Other chemopreventive a double blind randomized controlled trial targeting ACF
are under investigations [43-45].
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15. Difficulties or pitfalls in detection of ACF
All these data strongly suggest that ACF in the distal colon may be useful and reliable surrogate
marker in predicting CRC risk. However, there are also limitations and difficulties. The main
limitation is the fact that chromoendoscopy and magnifying endoscopes are largely research
tools and not the equipment in gastrointestinal practice. Difficulties were reported in some
studies in which endoscopic criteria failed to predict histologic confirmation of ACF or
correlation between the number of ACF and CRC risk [46; 47]. It was also found that there was
considerable variability among endoscopists regarding accuracy to correctly identify ACF. It
was found that in spite of training, accuracy to correctly identify ACF did not improve [46].
Current knowledge about rodents ACF, which share many similarities with human pathology,
might be helpful to understand tricks and traps when using ACF. In rodents, ACF are widely
accepted as intermediate biomarkers of CRC risk assessment. They have been used as an
endpoint in identifying and assessing preventive or promotional role of natural and pharma‐
cological compounds, as well as dietary and environmental factors in the process of colon
carcinogenesis [48; 49]. However, limitations to the use of ACF as a biomarker to identify cancer
preventive agents exist. Increasing number of studies has demonstrated that ACF in both
animals and humans are heterogeneous group of lesions that contain multiple genetic,
epigenetic and phenotypic alterations [15; 22; 50]. In rodents, total number of ACF may be
considered as a valid biomarker only at very early stage of carcinogenesis, while in subsequent
weeks ACF with higher crypt multiplicities (more than 4 crypts) are considered more specific
biomarker than total number of ACF. In more advanced stages of colon carcinogenesis ACF
may not be reliable intermediate biomarker of colon carcinogenesis (explained in detail in [9]
and [51]). It is also important to mention that ACF are not equally distributed among the
proximal, middle or distal colon. The majority of ACF develop in the middle and distal colon
[52-54], which need to be taken into consideration when using ACF as biomarkers (compre‐
hensively discussed in [9; 10] and [51]. Nevertheless, when considering all above mentioned
facts ACF are useful biomarkers for the screening of compounds for their chemopreventive
activities [49; 51].
16. Conclusion
Based on experimental and clinical studies evidence demonstrates that ACF share similar
histological and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas).
ACF exhibit many of the molecular and genetic abnormalities that form the basis for the
adenoma-carcinoma sequence in CRC. Today, high-magnification chromoscopic colonoscopy
allows detection and biopsy of ACF in vivo in man. It also provides opportunity to investigate
and characterize the earliest genetic and molecular alterations in CRC development in man.
However, it has been shown that ACF are heterogeneous group of lesions that exhibit variable
endoscopic, histological and molecular features. This fact has been shown to cause some
difficulties in accuracy of detection and quantification of ACF among endoscopists. However,
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chromoendoscopy and magnifying endoscopes are largely research tools and future research
on that field will bring new information about reliability and applicability of ACF as biomarker
of CRC risk in clinical practice.
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